Key result
Oral therapy with sucrosomial iron in patients with chronic heart failure and anemia significantly increased hemoglobin and ferritin levels, improved exercise tolerance, and reduced mortality over 2 years.
Why the study?
The study was conducted to describe anemia in chronic heart failure and evaluate the effectiveness of oral therapy with sucrosomial iron in this population.
Does oral sucrosomial iron improve clinical and laboratory outcomes in patients with chronic heart failure and anemia?
Observational (n=56)
Does oral sucrosomial iron improve clinical and laboratory outcomes in patients with chronic heart failure and anemia?
Answers are grounded in this paper and cite their sources.
Oral sucrosomial iron therapy in patients with chronic heart failure and anemia significantly improves hematological parameters, functional status, and mortality over 2 years.
The aim of this study is to describe anemia in chronic heart failure (CHF) and to evaluate the effectiveness of oral therapy with sucrosomial iron (SiderAL® Forte) in this group. Material and methods . The study included 56 patients with CHF and anemia. Results . Anemia in CHF corresponds to anemia of chronic disease (ACD) with the development of iron deficiency (ID) in 75% of patients. The use of sucrosomial iron leads to a significant increase in hemoglobin and serum ferritin levels, a decrease in the concentration of N-terminal pro-brain natriuretic peptide, an improvement in exercise tolerance, a reduction in the functional class of CHF, and a decrease in mortality over a 2-year follow-up period. Conclusion. The addition of iron preparations with hepcidin-independent absorption to standard CHF therapy shows a significant positive effect across all criteria and can be recommended for this category of patients in routine clinical practice.
No takes yet. Share an insight, caveat, or question.
Gurkina et al. (2025) conducted an observational in Chronic heart failure (CHF) and anemia (n=56). Sucrosomial iron (SiderAL® Forte) vs. Standard CHF therapy was evaluated on Hemoglobin, serum ferritin levels, NT-proBNP, exercise tolerance, functional class of CHF, and mortality. Oral therapy with sucrosomial iron in patients with chronic heart failure and anemia significantly increased hemoglobin and ferritin levels, improved exercise tolerance, and reduced mortality over 2 years.
Synapse has enriched 10 related papers. Consider them for comparative context: